1. Detection of Colorectal Disease by Stool Defensin Assay: An Exploratory Study 
Hongzhi Zou, Jonathan J. Harrington, Aravind Sugumar, Kristie K. Klatt, Thomas C. Smyrk, David A. Ahlquist 
Clinical Gastroenterology and Hepatology 
Volume 5, Issue 7, Pages (July 2007)
DOI: /j.cgh
Copyright © 2007 AGA Institute Terms and Conditions

2. Figure 1
The mRNA expression levels of HNP1-3 quantified by real-time reverse transcription–PCR in colon cancer cell lines (HT29, SW480, SNUC4, SW620, HCT15, and WIDR), CRC tissues, normal (NL) colorectal epithelia, white blood cells, and neutrophils. HNP1-3 levels in CRC and NL were only plotted with medians here.
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

3. Figure 2
The protein concentration of HNP1-3 quantified by ELISA in stools from normal individuals, patients with CRC, colorectal adenoma, upper gastrointestinal cancers (UGC), and IBD. Each circle represents a stool sample. The solid horizontal bar indicates the mean of HNP1-3 concentration within a group of subjects.
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

4. Figure 3
Correlation of HNP1-3 protein with lactoferrin, a known inflammatory marker, in stool samples. Correlation was significant (R2 = 0.70, P < .001).
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions